Cargando…
The impact of Rotavirus mass vaccination on hospitalization rates, nosocomial Rotavirus gastroenteritis and secondary blood stream infections
BACKGROUND: The aim of the study was to evaluate the effects of universal mass vaccination (UMV) against rotavirus (RV) on the hospitalization rates, nosocomial RV infections and RV-gastroenteritis (GE)-associated secondary blood stream infections (BSI). METHODS: The retrospective evaluation (2002–2...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3599253/ https://www.ncbi.nlm.nih.gov/pubmed/23452879 http://dx.doi.org/10.1186/1471-2334-13-112 |
_version_ | 1782262921520218112 |
---|---|
author | Zlamy, Manuela Kofler, Sabine Orth, Dorothea Würzner, Reinhard Heinz-Erian, Peter Streng, Andrea Prelog, Martina |
author_facet | Zlamy, Manuela Kofler, Sabine Orth, Dorothea Würzner, Reinhard Heinz-Erian, Peter Streng, Andrea Prelog, Martina |
author_sort | Zlamy, Manuela |
collection | PubMed |
description | BACKGROUND: The aim of the study was to evaluate the effects of universal mass vaccination (UMV) against rotavirus (RV) on the hospitalization rates, nosocomial RV infections and RV-gastroenteritis (GE)-associated secondary blood stream infections (BSI). METHODS: The retrospective evaluation (2002–2009) by chart analysis included all clinically diagnosed and microbiologically confirmed RV-GE cases in a large tertiary care hospital in Austria. The pre-vaccination period (2002–2005) was compared with the recommended and early funded (2006–2007) and the funded (2008–2009) vaccination periods. Primary outcomes were RV-GE-associated hospitalizations, secondary outcomes nosocomial RV disease, secondary BSI and direct hospitalization costs for children and their accompanying persons. RESULTS: In 1,532 children with RV-GE, a significant reduction by 73.9% of hospitalized RV-GE cases per year could be observed between the pre-vaccination and the funded vaccination period, which was most pronounced in the age groups 0–11 months (by 87.8%), 6–10 years (by 84.2%) and 11–18 years (88.9%). In the funded vaccination period, a reduction by 71.9% of nosocomial RV-GE cases per year was found compared to the pre-vaccination period. Fatalities due to nosocomial RV-GE were only observed in the pre-vaccination period (3 cases). Direct costs of hospitalized, community-acquired RV-GE cases per year were reduced by 72.7% in the funded vaccination period. The reduction of direct costs for patients (by 86.9%) and accompanying persons (86.2%) was most pronounced in the age group 0–11 months. CONCLUSIONS: UMV may have contributed to the significant decrease of RV-GE-associated hospitalizations, to a reduction in nosocomial RV infections and RV-associated morbidity due to secondary BSI and reduced direct hospitalization costs. The reduction in nosocomial cases is an important aspect considering severe disease courses in hospitalized patients with co-morbidities and death due to nosocomial RV-GE. |
format | Online Article Text |
id | pubmed-3599253 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-35992532013-03-17 The impact of Rotavirus mass vaccination on hospitalization rates, nosocomial Rotavirus gastroenteritis and secondary blood stream infections Zlamy, Manuela Kofler, Sabine Orth, Dorothea Würzner, Reinhard Heinz-Erian, Peter Streng, Andrea Prelog, Martina BMC Infect Dis Research Article BACKGROUND: The aim of the study was to evaluate the effects of universal mass vaccination (UMV) against rotavirus (RV) on the hospitalization rates, nosocomial RV infections and RV-gastroenteritis (GE)-associated secondary blood stream infections (BSI). METHODS: The retrospective evaluation (2002–2009) by chart analysis included all clinically diagnosed and microbiologically confirmed RV-GE cases in a large tertiary care hospital in Austria. The pre-vaccination period (2002–2005) was compared with the recommended and early funded (2006–2007) and the funded (2008–2009) vaccination periods. Primary outcomes were RV-GE-associated hospitalizations, secondary outcomes nosocomial RV disease, secondary BSI and direct hospitalization costs for children and their accompanying persons. RESULTS: In 1,532 children with RV-GE, a significant reduction by 73.9% of hospitalized RV-GE cases per year could be observed between the pre-vaccination and the funded vaccination period, which was most pronounced in the age groups 0–11 months (by 87.8%), 6–10 years (by 84.2%) and 11–18 years (88.9%). In the funded vaccination period, a reduction by 71.9% of nosocomial RV-GE cases per year was found compared to the pre-vaccination period. Fatalities due to nosocomial RV-GE were only observed in the pre-vaccination period (3 cases). Direct costs of hospitalized, community-acquired RV-GE cases per year were reduced by 72.7% in the funded vaccination period. The reduction of direct costs for patients (by 86.9%) and accompanying persons (86.2%) was most pronounced in the age group 0–11 months. CONCLUSIONS: UMV may have contributed to the significant decrease of RV-GE-associated hospitalizations, to a reduction in nosocomial RV infections and RV-associated morbidity due to secondary BSI and reduced direct hospitalization costs. The reduction in nosocomial cases is an important aspect considering severe disease courses in hospitalized patients with co-morbidities and death due to nosocomial RV-GE. BioMed Central 2013-03-01 /pmc/articles/PMC3599253/ /pubmed/23452879 http://dx.doi.org/10.1186/1471-2334-13-112 Text en Copyright ©2013 Zlamy et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Zlamy, Manuela Kofler, Sabine Orth, Dorothea Würzner, Reinhard Heinz-Erian, Peter Streng, Andrea Prelog, Martina The impact of Rotavirus mass vaccination on hospitalization rates, nosocomial Rotavirus gastroenteritis and secondary blood stream infections |
title | The impact of Rotavirus mass vaccination on hospitalization rates, nosocomial Rotavirus gastroenteritis and secondary blood stream infections |
title_full | The impact of Rotavirus mass vaccination on hospitalization rates, nosocomial Rotavirus gastroenteritis and secondary blood stream infections |
title_fullStr | The impact of Rotavirus mass vaccination on hospitalization rates, nosocomial Rotavirus gastroenteritis and secondary blood stream infections |
title_full_unstemmed | The impact of Rotavirus mass vaccination on hospitalization rates, nosocomial Rotavirus gastroenteritis and secondary blood stream infections |
title_short | The impact of Rotavirus mass vaccination on hospitalization rates, nosocomial Rotavirus gastroenteritis and secondary blood stream infections |
title_sort | impact of rotavirus mass vaccination on hospitalization rates, nosocomial rotavirus gastroenteritis and secondary blood stream infections |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3599253/ https://www.ncbi.nlm.nih.gov/pubmed/23452879 http://dx.doi.org/10.1186/1471-2334-13-112 |
work_keys_str_mv | AT zlamymanuela theimpactofrotavirusmassvaccinationonhospitalizationratesnosocomialrotavirusgastroenteritisandsecondarybloodstreaminfections AT koflersabine theimpactofrotavirusmassvaccinationonhospitalizationratesnosocomialrotavirusgastroenteritisandsecondarybloodstreaminfections AT orthdorothea theimpactofrotavirusmassvaccinationonhospitalizationratesnosocomialrotavirusgastroenteritisandsecondarybloodstreaminfections AT wurznerreinhard theimpactofrotavirusmassvaccinationonhospitalizationratesnosocomialrotavirusgastroenteritisandsecondarybloodstreaminfections AT heinzerianpeter theimpactofrotavirusmassvaccinationonhospitalizationratesnosocomialrotavirusgastroenteritisandsecondarybloodstreaminfections AT strengandrea theimpactofrotavirusmassvaccinationonhospitalizationratesnosocomialrotavirusgastroenteritisandsecondarybloodstreaminfections AT prelogmartina theimpactofrotavirusmassvaccinationonhospitalizationratesnosocomialrotavirusgastroenteritisandsecondarybloodstreaminfections AT zlamymanuela impactofrotavirusmassvaccinationonhospitalizationratesnosocomialrotavirusgastroenteritisandsecondarybloodstreaminfections AT koflersabine impactofrotavirusmassvaccinationonhospitalizationratesnosocomialrotavirusgastroenteritisandsecondarybloodstreaminfections AT orthdorothea impactofrotavirusmassvaccinationonhospitalizationratesnosocomialrotavirusgastroenteritisandsecondarybloodstreaminfections AT wurznerreinhard impactofrotavirusmassvaccinationonhospitalizationratesnosocomialrotavirusgastroenteritisandsecondarybloodstreaminfections AT heinzerianpeter impactofrotavirusmassvaccinationonhospitalizationratesnosocomialrotavirusgastroenteritisandsecondarybloodstreaminfections AT strengandrea impactofrotavirusmassvaccinationonhospitalizationratesnosocomialrotavirusgastroenteritisandsecondarybloodstreaminfections AT prelogmartina impactofrotavirusmassvaccinationonhospitalizationratesnosocomialrotavirusgastroenteritisandsecondarybloodstreaminfections |